Guideline on pharmaceutical development of medicines for paediatric use
ثبت نشده
چکیده
Draft Agreed by QWP February 2011 Draft agreed by SWP March 2011 Draft agreed by PDCO April 2011 Adoption by CHMP for release for consultation May 2011 End of consultation (deadline for comments) 31 December 2011 Revised version agreed by QWP for release for second consultation September 2012 Revised version agreed by PDCO for release for second consultation November 2012 Revised version adopted by CHMP for release for second consultation November 2012 End of second consultation (deadline for comments) 31 March 2013 8 Comments should be provided using this template. The completed comments form should be sent to [email protected] 9
منابع مشابه
Draft guideline on pharmaceutical development of medicines for paediatric use
End of consultation (deadline for comments) 31 December 2011 7 8 Comments should be provided using this template. The completed comments form should be sent to [email protected] 9
متن کاملDeveloping paediatric medicines: identifying the needs and recognizing the challenges.
There is a significant need for research and development into paediatric medicines. Only a small fraction of the drugs marketed and utilized as therapeutic agents in children have been clinically evaluated. The majority of marketed drugs are either not labelled, or inadequately labelled, for use in paediatric patients. The absence of suitable medicines or critical safety and efficacy informatio...
متن کاملFramework conditions facilitating paediatric clinical research
The use of unlicensed and "off-label" medicines in children is widespread. Between 50-80% of the medicines currently administered to children have neither been tested nor authorized for their use in the paediatric population which represents approximately 25% of the whole European population. On 26 January 2007, entered into force the European Regulation of Paediatric Medicines. It aims at the ...
متن کاملPharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective
A large proportion of medicines used in children are prescribed off-label, and children have often been denied access to new or innovative medications. Because such situation is unethical, the need to obtain paediatric information for medicines used in children seems nowadays a matter of consensus on a global basis. Based on this, it was clear in EU, like what has happened in the US, that there...
متن کاملThe european paediatric legislation: benefits and perspectives
BACKGROUND The lack of availability of appropriate medicines for children is an extensive and well known problem. Paediatricians and Physicians who take care of the paediatric population are primarily exposed to cope with this negative situation very often as more than half of the children are prescribed off-label or unlicensed medicines. DISCUSSION Medicinal products used to treat this popul...
متن کامل